Browse Category

NYSE:PFE 4 February 2026 - 8 May 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.

Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus

Novavax surged roughly 13% by Friday afternoon, building on gains after its quarterly results. The vaccine manufacturer topped first-quarter revenue expectations, driven more by licensing and supply agreements than any recovery in COVID-19 vaccine demand. Shares were changing hands at $10.45, with intraday volume topping 8.4 million, market data showed.

8 May 2026

NASDAQ:NVAX·NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

Pfizer turned in a first-quarter profit that beat forecasts on Tuesday, thanks in large part to solid demand for established drugs like the blood thinner Eliquis and cancer therapy Padcev, cushioning the impact of another steep fall in sales of its COVID offerings. Adjusted earnings landed at 75 cents per share, with revenue reaching $14.45 billion—both topping Wall Street’s consensus for 72 cents per share and $13.79 billion in revenue, according to Reuters.

5 May 2026

Earnings Reports·NYSE:PFE·Pharmaceuticals·Stock Market

US Stock Market Today: Dow, S&P 500 and Nasdaq Futures Rise as Oil Pullback Gives Wall Street a Narrow Opening

Tuesday morning saw U.S. stock index futures ticking higher, with oil prices dropping back slightly after Middle East jitters dragged the S&P 500 off its highs the previous day. By 5:35 a.m. ET, Dow e-minis had added 124 points, or 0.25%. S&P 500 e-minis were 0.33% higher, while Nasdaq 100 e-minis picked up 0.58%. Brent crude slipped but remained above the $110 mark.

5 May 2026

NASDAQ:AMD·NYSE:KKR·NYSE:PFE·Stock Market

Pfizer Just Got a First-of-Its-Kind Breast Cancer Approval. The Bigger Test Comes This Week

Pfizer Inc. and Arvinas scored FDA approval for Veppanu, a breast cancer pill, adding a fresh weapon to Pfizer’s oncology lineup. With this nod, Pfizer gains ground in its push to prove it can replace waning sales from legacy products after the COVID boom.

3 May 2026

NASDAQ:ARVN·NYSE:PFE·Pharmaceutical Industry

Pfizer Stock in Focus After FDA Priority Review as Padcev, Obesity Bets Drive Post-COVID Reset

Pfizer picked up a new short-term catalyst Monday, with the U.S. Food and Drug Administration handing a priority review to its Padcev submission for bladder cancer. The stock gained roughly 0.8%, trading at $27.78 in the afternoon, drawing renewed attention as the company pushes ahead with a wider pipeline.

20 April 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer Stock Faces Fresh Questions as Aberdeen, Stratos and Raab & Moskowitz Trim Stakes

Between April 3 and April 6, a trio of reports drawing on fourth-quarter 13F filings detailed that Aberdeen Group, Raab & Moskowitz Asset Management, and Stratos Wealth Partners each cut back on Pfizer positions—together unloading 740,174 shares. On Monday, Pfizer stock slipped roughly 0.7% to $28.12 in U.S. trading.

6 April 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Is Pfizer Stock a Buy? Shares Hit Fresh High as Bulls and Bears Clash Over Valuation

Pfizer hit a new 52-week high Tuesday, lifted by upbeat analyst notes and a string of pipeline news fueling demand. Shares last changed hands at $27.87 late in the morning, having reached $28.30 earlier—eclipsing the earlier high-water mark of $27.92.

31 March 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer Inc. slipped about 1% to close at $26.60 on Friday, landing near the session’s low as investors digested fresh developments in the respiratory syncytial virus vaccine landscape and a boost for blood thinner Eliquis. The pressure came after GSK announced the FDA had expanded Arexvy’s approval to include at-risk adults 18 to 49. Meanwhile, separate results highlighted strong outcomes for Eliquis in treating serious blood clots.

13 March 2026

NYSE:PFE·Pfizer News·Pharmaceuticals·Stock Market

Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer ended Thursday down 1.6% at $26.86, caught up in a sweeping selloff across U.S. equities. Oil prices jumped on intensifying Middle East tensions, and the slide hit all three major indexes—S&P 500, Dow, and Nasdaq—each losing over 1.5%.

12 March 2026

NYSE:PFE·Pfizer·Pharmaceuticals·Stock Market

Pfizer Stock Price Today: PFE Slips as mRNA Vaccine Worry Eases, Eczema Data Offers Fresh Catalyst

Pfizer slipped roughly 0.4% to $27.05 midday Wednesday in New York. Investors reacted after the Washington Post said U.S. vaccine advisers scrapped plans to scrutinize mRNA COVID vaccines, removing a potential regulatory obstacle for the company’s vaccine segment.

11 March 2026

NYSE:PFE·Pfizer News·Pharmaceuticals·Stock Market

Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson on Tuesday said it’s filed with the European Medicines Agency to expand Tecvayli’s EU label, aiming to allow the therapy as a single agent for adults with relapsed or refractory multiple myeloma who’ve already had at least one prior treatment. That would move the drug up in the treatment sequence for the blood cancer, where, according to the company, patients still encounter some of the toughest care gaps.

10 March 2026

NYSE:BMY·NYSE:JNJ·NYSE:PFE·Stock Market

Pfizer eczema drug clears Phase 2, sets up a fresh challenge to Dupixent

Pfizer’s experimental eczema treatment, tilrekimig, hit its main target in a mid-stage trial, the company said Monday. That outcome sets up a late-stage study slated for later this year, pushing Pfizer nearer to a market still dominated by Sanofi and Regeneron’s Dupixent.

9 March 2026

NYSE:PFE·Pharmaceuticals

Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer slipped 0.3% to $27.52 ahead of the bell Wednesday, following a 2.1% gain Tuesday that took shares to $27.61. The stock hit $27.73 during the session, with trading volume reaching roughly 43.6 million shares.

11 February 2026

NYSE:PFE·Pfizer·Pharmaceuticals·Stock Market

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

Pfizer Inc closed out Friday at $27.22, notching a 2.8% gain. Shares fluctuated from $26.52 to $27.37 throughout the session, with volume hitting roughly 50.7 million shares.

7 February 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus

Pfizer shares climbed 72 cents, or 2.7%, to $27.22 in afternoon trading Friday, outpacing the SPDR S&P 500 ETF’s roughly 1.7% gain. Roughly 30 million Pfizer shares traded hands.

6 February 2026

Healthcare News·NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer stock slips before open as TrumpRx discounts debut and FDA priority review adds a catalyst

Pfizer Inc shares slipped roughly 1.1% to $26.49 in premarket action Friday, following Thursday’s close near $26.79.

6 February 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer stock faces a Friday test after TrumpRx discounts hit the tape

Pfizer shares slipped 1.1% to close at $26.49 on Thursday, ahead of the company’s launch of fresh discounts linked to the TrumpRx platform. During the day, the stock fluctuated between $26.46 and $27.19.

6 February 2026

NYSE:PFE·Pfizer News·Pharmaceuticals·Stock Market

Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer shares climbed 0.8% to $27.01 by 12:43 p.m. EST, building on a rebound after a volatile stretch triggered by fresh trial data and a quarterly earnings report.

5 February 2026

NYSE:PFE·Pfizer·Pharmaceuticals·Stock Market

Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop

Pfizer Inc shares gained 3.9%, closing at $26.78 on Wednesday, then held steady in after-hours trading. The move capped a volatile two days driven by fresh obesity drug data and quarterly earnings.

5 February 2026

NYSE:PFE·Pharmaceuticals

Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus

Pfizer Inc shares climbed roughly 3.7% to $26.73 by early Wednesday afternoon, bouncing back after a roughly 3.3% drop the previous day.

4 February 2026

NYSE:PFE·Pharmaceutical Industry·Stock Market

Previous 1 2 3 4 5 … 12 Next

NYSE:PFE 4 February 2026 - 8 May 2026

Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus

Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

US Stock Market Today: Dow, S&P 500 and Nasdaq Futures Rise as Oil Pullback Gives Wall Street a Narrow Opening

Pfizer Just Got a First-of-Its-Kind Breast Cancer Approval. The Bigger Test Comes This Week

Pfizer Stock in Focus After FDA Priority Review as Padcev, Obesity Bets Drive Post-COVID Reset

Pfizer Stock Faces Fresh Questions as Aberdeen, Stratos and Raab & Moskowitz Trim Stakes

Is Pfizer Stock a Buy? Shares Hit Fresh High as Bulls and Bears Clash Over Valuation

Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer Stock Price Today: PFE Slips as mRNA Vaccine Worry Eases, Eczema Data Offers Fresh Catalyst

Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Pfizer eczema drug clears Phase 2, sets up a fresh challenge to Dupixent

Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus

Pfizer stock slips before open as TrumpRx discounts debut and FDA priority review adds a catalyst

Pfizer stock faces a Friday test after TrumpRx discounts hit the tape

Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop

Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus

TechStock² Updates

Berkshire Hathaway’s $7.8 Billion Repurchase Strategy Puts Greg Abel to the Test on Monday

Airbnb (NASDAQ:ABNB) Rallies 17% With AI Savings Sending Stock Past Wall Street Target

DoubleVerify (NYSE:DV) faces 3% remaining upside as deal with Nielsen pushes expected close to 2027

Bob’s Discount Furniture (NYSE:BOBS) meets 11.4% margin challenge in H2

The Trade Desk (NASDAQ:TTD) Drops 21.9% as Q3 Outlook Points to 25% Adjusted EBITDA Margin

Top Stock Picks

AerCap

Constellation Energy

Cheniere Energy

Walt Disney

AIG

Live updates

Investment Disclaimer